Ensign Peak Advisors’s BioCryst Pharmaceuticals BCRX Stock Holding History

Ensign Peak Advisors’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$175K	Buy	17,450 +3,050	+21%	+$27.6K	﹤0.01%	1445
2026 Q1	$137K	Hold	14,400	–	–	﹤0.01%	1483
2025 Q4	$112K	Sell	14,400 -32,400	-69%	-$234K	﹤0.01%	1544
2025 Q3	$355K	Sell	46,800 -41,600	-47%	-$346K	﹤0.01%	1527
2025 Q2	$792K	Hold	88,400	–	–	﹤0.01%	1383
2025 Q1	$663K	Hold	88,400	–	–	﹤0.01%	1456
2024 Q4	$665K	Hold	88,400	–	–	﹤0.01%	1518
2024 Q3	$672K	Hold	88,400	–	–	﹤0.01%	1521
2024 Q2	$546K	Hold	88,400	–	–	﹤0.01%	1581
2024 Q1	$449K	Sell	88,400 -4,460	-5%	-$25.1K	﹤0.01%	1646
2023 Q4	$556K	Hold	92,860	–	–	﹤0.01%	1638
2023 Q3	$657K	Hold	92,860	–	–	﹤0.01%	1479
2023 Q2	$654K	Hold	92,860	–	–	﹤0.01%	1535
2023 Q1	$774K	Buy	92,860 +11,300	+14%	+$109K	﹤0.01%	1441
2022 Q4	$936K	Buy	81,560 +28,200	+53%	+$352K	﹤0.01%	1216
2022 Q3	$672K	Buy	53,360 +1,530	+3%	+$19.7K	﹤0.01%	1302
2022 Q2	$548K	Hold	51,830	–	–	﹤0.01%	1425
2022 Q1	$843K	Hold	51,830	–	–	﹤0.01%	1300
2021 Q4	$718K	Buy	+51,830	New	+$686K	﹤0.01%	1450

Other funds holding BCRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Jupiter Topco New York $245B AUM

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Ensign Peak Advisors's BCRX Position: Q2 2026 in Review

Ensign Peak Advisors increased its BioCryst Pharmaceuticals (BCRX) stake by 21% in Q2 2026, buying an estimated $27.6K and bringing the position to 17,450 shares worth $175K. The position accounts for ﹤0.01% of the portfolio, ranked #1445.

Ensign Peak Advisors first reported a position in BCRX in Q4 2021 and has held it in 19 quarters since. The position peaked at $936K in Q4 2022. 318 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

Ensign Peak Advisors held 17,450 shares of BioCryst Pharmaceuticals worth $175K as of Q2 2026.
Ensign Peak Advisors bought 3,050 BioCryst Pharmaceuticals shares in Q2 2026, an estimated $27.6K.
BioCryst Pharmaceuticals made up ﹤0.01% of Ensign Peak Advisors's portfolio in Q2 2026, its #1445 holding.
Ensign Peak Advisors first reported a position in BioCryst Pharmaceuticals in Q4 2021 and has held it in 19 quarters since.
Ensign Peak Advisors's BioCryst Pharmaceuticals position peaked at $936K in Q4 2022.
318 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on Ensign Peak Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.